Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Aug 21:9:531-536.
doi: 10.2147/BCTT.S111397. eCollection 2017.

Increased risk of breast cancer in neurofibromatosis type 1: current insights

Sacha J Howell  1 , Kimberley Hockenhull  1 , Zena Salih  1 , D Gareth Evans  2   3
Affiliations
Review

Increased risk of breast cancer in neurofibromatosis type 1: current insights

Sacha J Howell et al. Breast Cancer (Dove Med Press). .

Abstract

Neurofibromatosis type 1 (NF1) is an autosomal dominant condition caused by mutation/deletion of the NF1 gene. The gene product, neurofibromin, is a tumor suppressor which represses the activity of the Ras oncogene. Central nervous system (CNS) tumors have long been associated with NF1, but their association with several other malignancies has been demonstrated. In this review, we summarize the epidemiological data that irrefutably support a link between NF1 and an increased risk of early-onset breast cancer, to levels at which annual mammography is currently recommended in national high-risk screening programs. We discuss the reasons for the observed adverse breast cancer prognosis in NF1 cases, including late presentation and more aggressive tumor subtypes, and recommend that a collaborative breast screening study be initiated to better serve this currently underserved population of women.

Keywords: NF1; breast cancer; neurofibromatosis type 1.

PubMed Disclaimer

Conflict of interest statement

Disclosure The authors report no conflicts of interest in this work.

References

    1. Evans DG, Howard E, Giblin C, et al. Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service. Am J Med Genet A. 2010;152A(2):327–332. - PubMed
    1. Uusitalo E, Leppävirta J, Koffert A, et al. Incidence and mortality of neurofibromatosis: a total population study in Finland. J Invest Dermatol. 2015;135(3):904–906. - PubMed
    1. Easton DF, Ponder MA, Huson SM, Ponder BA. An analysis of variation in expression of neurofibromatosis (NF) type 1 (NF1): evidence for modifying genes. Am J Hum Genet. 1993;53(2):305–313. - PMC - PubMed
    1. Abramowicz A, Gos M. Neurofibromin in neurofibromatosis type 1 – mutations in NF1 gene as a cause of disease. Dev Period Med. 2014;18(3):297–306. - PubMed
    1. Evans DG, Bowers N, Burkitt-Wright E, et al. Northern UK NF1 Research Network Comprehensive RNA analysis of the NF1 gene in classically affected NF1 meeting NIH criteria has high sensitivity and mutation negative testing is reassuring in isolated cases with pigmentary features only. EBioMedicine. 2016;7:212–220. - PMC - PubMed